Effect of long-term olanzapine treatment on meal-induced insulin sensitization and on gastrointestinal peptides in female Sprague-Dawley rats

Journal of Psychopharmacology
Csaba HegedűsBarna Peitl

Abstract

Meal-induced insulin sensitization (MIS), an endogenous adaptive mechanism is activated post-prandially. Reduced MIS leads to diabetes, but its activation improves insulin sensitivity. MIS is preserved to single olanzapine administration, therefore we aimed to investigate the chronic effect of olanzapine on fasted-state insulin sensitivity and on MIS in female Sprague-Dawley rats. Daily food and water intake, stool and urine production and body weight were determined. The MIS was characterized by a rapid insulin sensitivity test. Fasting hepatic and peripheral insulin sensitivity were determined by a hyperinsulinaemic euglycaemic glucose clamping supplemented with radiotracer technique. Fasted and post-prandial blood samples were obtained for plasma insulin, leptin, ghrelin, amylin, GLP-1, GIP, PYY and PP determination. Adiposity was characterized by weighing intra-abdominal and inguinal fat pads. Olanzapine caused hepatic insulin resistance and a reduced metabolic clearance rate of insulin, but the MIS retained its function. Body weight and adiposity were enhanced, but olanzapine failed to increase food intake. Fasting insulin and leptin were elevated and the post-prandial reduction in ghrelin level was inhibited by olanzapine...Continue Reading

References

Jul 1, 1980·Circulation Research·S WallensteinJ L Fleiss
Feb 1, 1996·The New England Journal of Medicine·R V ConsidineT L Bauer
Jan 16, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·J Arnt, T Skarsfeldt
Oct 21, 1998·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·X M GaoC A Tamminga
Oct 8, 1999·Clinical Pharmacokinetics·J T CallaghanC M Beasley
Jun 1, 2000·The American Journal of Psychiatry·D C HendersonD C Goff
Jun 28, 2000·Biopharmaceutics & Drug Disposition·M AravagiriS R Marder
Nov 1, 2000·Nature·M TschöpM L Heiman
Apr 6, 2001·Diabetes·M TschöpM L Heiman
Oct 16, 2001·The Journal of Clinical Endocrinology and Metabolism·M J Quon
Jul 9, 2002·Diabetic Medicine : a Journal of the British Diabetic Association·T M Wallace, D R Matthews
Oct 9, 2002·International Journal of Experimental Diabetes Research·M T VelasqueC T Hansen
May 22, 2003·Pharmacology, Biochemistry, and Behavior·B PouzetS Velschow
Sep 11, 2004·Psychoneuroendocrinology·Mari MurashitaTsukasa Koyama
Mar 22, 2005·Psychopharmacology·G D CooperA J Goudie
May 7, 2005·Metabolism: Clinical and Experimental·Barna PeitlZoltán Szilvássy
May 20, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Murray A RaskindDennis D Rasmussen
Sep 7, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Barna PeitlZoltán Szilvássy
Oct 13, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen L HouseknechtHans Rollema
May 25, 2007·European Journal of Pharmacology·László HerczegBarna Peitl
Aug 5, 2008·Schizophrenia Research·Araba F ChintohGary Remington
Feb 17, 2009·Metabolism: Clinical and Experimental·Barna PeitlZoltán Szilvássy
Apr 25, 2009·The Journal of Clinical Psychiatry·John M KaneSheila Assunção-Talbott
Oct 21, 2009·Schizophrenia Research·Katrina Weston-GreenChao Deng
Apr 24, 2010·The Journal of Pharmacology and Experimental Therapeutics·Lihong ChenXiaozhou Yao
May 19, 2010·Pharmacology, Biochemistry, and Behavior·Esther M van der ZwaalRoger A H Adan
Aug 3, 2010·Trends in Pharmacological Sciences·Heidi N BoydaAlasdair M Barr
Nov 9, 2010·Behavioural Brain Research·Katrina Weston-GreenChao Deng
Oct 11, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Katrina Weston-GreenChao Deng
Mar 6, 2013·Canadian Journal of Physiology and Pharmacology·Kawshik K ChowdhuryW Wayne Lautt
Aug 21, 2013·Psychoneuroendocrinology·Qingsheng ZhangXu-Feng Huang

❮ Previous
Next ❯

Citations

Sep 12, 2017·Journal of Psychopharmacology·Gavin P Reynolds, Olga O McGowan
Nov 15, 2017·Nordic Journal of Psychiatry·Özgür Korhan TunçelEbru Kaynar Tunçel

❮ Previous
Next ❯

Methods Mentioned

BETA
sedation

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.